2. GPCR/G Protein
  3. Guanylate Cyclase
  4. LY83583

LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease.

For research use only. We do not sell to patients.

LY83583

LY83583 Chemical Structure

CAS No. : 91300-60-6

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of LY83583:

LY83583 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE LY83583

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease[1][2][3][4].

In Vitro

LY83583 (1 μM, 4 d) induces morphological changes characteristic of senescence and senescence-associated β-galactosidase (SA-β-gal) staining at pH 6 in early-passage HDFs[1].
LY83583 (0.25-1.5 μM, 3 d) inhibits proliferation of early-passage HDFs, HCT116 and DLD1 colorectal cancer cell lines, MCF7 breast cancer cells and A-375 melanoma cells[1].
LY83583 (1 μM, 24-36 h) almost completely blocks HDF entry into the S phase after release from G1 phase synchronization by confluence, and inhibits DNA synthesis detected by BrdU incorporation[1].
LY83583 (1 μM, 3-6 h) induces p21 protein expression in HDFs[1].
LY83583 (1 μM, 6 h) shifts the phosphorylation status of pRb in HDFs toward the hypophosphorylated form[1].
LY83583 (1 μM, 2 h) inhibits SNP-induced cGMP synthesis in early-passage HDFs[1].
LY-83583 (10 μM, 1 h) stimulates cytochalasin B-inhibitable [3H]3-O-methyl-D-glucose uptake in Clone 9 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LY83583 Related Antibodies
In Vivo

LY83583 (10 μM, topical application via cranial window, 15 min) completely inhibits Nitroprusside (HY-B0564)-induced vasodilation of cerebral arterioles or calcitonin gene-related peptide (CGRP)-induced vasodilation in anesthetized cats[2].
LY83583 (100 μg dissolved in 5 μL 20% DMSO, i.c.v., once) significantly and persistently decreases REMS duration and increases NREMS duration in male rats[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Anesthetized cats (2-3.5 kg)[2]
Dosage: 10 μM
Administration: topical application via cranial window, 15 min
Result: Inhibited Nitroprusside (HY-B0564)-induced vasodilation of cerebral arterioles or calcitonin gene-related peptide (CGRP)-induced vasodilation.
Animal Model: Male Sprague-Dawley rats (275-400 g)[4]
Dosage: 100 μg dissolved in 5 μL 20% DMSO
Administration: i.c.v., once
Result: Decreased REMS duration and increased NREMS duration.
Increased EEG delta-wave power during NREMS and suppressed theta, alpha, beta-wave powers in NREMS/wakefulness.
Molecular Weight

250.26

Formula

C15H10N2O2
CAS No.
Appearance

Solid

Color

Brown to red

SMILES

O=C1C=C(NC2=CC=CC=C2)C(C3=C1N=CC=C3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 200 mg/mL (799.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.9958 mL 19.9792 mL 39.9584 mL
5 mM 0.7992 mL 3.9958 mL 7.9917 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.9958 mL 19.9792 mL 39.9584 mL 99.8961 mL
5 mM 0.7992 mL 3.9958 mL 7.9917 mL 19.9792 mL
10 mM 0.3996 mL 1.9979 mL 3.9958 mL 9.9896 mL
15 mM 0.2664 mL 1.3319 mL 2.6639 mL 6.6597 mL
20 mM 0.1998 mL 0.9990 mL 1.9979 mL 4.9948 mL
25 mM 0.1598 mL 0.7992 mL 1.5983 mL 3.9958 mL
30 mM 0.1332 mL 0.6660 mL 1.3319 mL 3.3299 mL
40 mM 0.0999 mL 0.4995 mL 0.9990 mL 2.4974 mL
50 mM 0.0799 mL 0.3996 mL 0.7992 mL 1.9979 mL
60 mM 0.0666 mL 0.3330 mL 0.6660 mL 1.6649 mL
80 mM 0.0499 mL 0.2497 mL 0.4995 mL 1.2487 mL
100 mM 0.0400 mL 0.1998 mL 0.3996 mL 0.9990 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LY83583 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LY8358391300-60-6LY 83583LY-83583Guanylate CyclaseCancerscardiovascular diseasesGCcGMPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LY83583
Cat. No.:
HY-W013386
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.